Key result
Biological AVR linked to ~31% fewer major adverse events and similar survival versus mechanical valves.
Why the study?
Current guidelines for aortic valve replacement lack consensus on prosthesis selection in middle-aged patients.
Do biological prostheses reduce mortality or major adverse prosthesis-related events compared to mechanical prostheses in middle-aged patients undergoing aortic valve replacement?
Cohort (n=2,272)
Yes
Do biological prostheses reduce mortality or major adverse prosthesis-related events compared to mechanical prostheses in middle-aged patients undergoing aortic valve replacement?
In middle-aged Asian patients undergoing aortic valve replacement, biological prostheses offer similar long-term survival but fewer major adverse events compared to mechanical prostheses, particularly in those aged 55-64.
Answers are grounded in this paper and cite their sources.
May favor biological prostheses in middle-aged AVR patients; hypothesis-generating and should not change practice without RCTs.
BACKGROUND: Current guidelines for aortic valve replacement (AVR) lack consensus on prosthesis selection in middle-aged patients. This study aimed to provide a comprehensive comparison of long-term outcomes following AVR with mechanical versus biological prostheses among middle-aged patients in an Asian population. METHODS: This retrospective cohort study used Taiwan's national claims database, including patients aged 45-64 years who underwent AVR between 2006 and 2021 across 46 hospitals. Propensity score matching was applied to achieve covariate balance. Risks of all-cause mortality and major adverse prosthesis-related events (major bleeding, ischaemic stroke, aortic valve reoperation, endocarditis and sudden cardiac death) were compared using restricted mean survival time (RMST) and subdistribution HRs (sHRs) to account for competing risks. Subgroup analyses were performed for patients aged 45-54 and 55-64 years. RESULTS: A total of 1136 matched pairs of patients with biological or mechanical prostheses were included, with follow-up of up to 17 years. In the overall cohort, all-cause mortality did not significantly differ between prosthesis groups. However, patients with biological prostheses experienced fewer major adverse prosthesis-related events (10-year RMST difference: 0.68 years; 95% CI: 0.38 to 0.98; sHR: 0.69; 95% CI: 0.59 to 0.81). In age-stratified analyses, outcomes were comparable between types in patients aged 45-54, whereas biological prostheses were associated with similar survival but fewer adverse events in those aged 55-64. CONCLUSIONS: Among middle-aged Asian patients undergoing AVR, biological and mechanical prostheses yield similar long-term survival, yet biological prostheses carry a lower risk of major adverse events, especially in those aged 55-64. Opting for biological prostheses at a younger age, potentially starting at age 55, may offer advantages in improving long-term outcomes.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2025) conducted a cohort in Aortic valve replacement (n=2,272). Biological prostheses vs. Mechanical prostheses was evaluated on All-cause mortality and major adverse prosthesis-related events (sHR 0.69, 95% CI 0.59-0.81). Biological prostheses for aortic valve replacement yielded similar survival to mechanical prostheses but fewer major adverse events, especially in patients aged 55-64.
Synapse has enriched 10 related papers. Consider them for comparative context: